Integrin

Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 16, 2024
Integrin, Lung cancer, Safety, Colorectal cancer, Prognosis, Immunosuppression, STAT3, Growth, IND, ADCC, CCR8, Fibrosis, Neoplasm, AACR, Carcinoma, Vaccine

As an important inflammation factor, IL-11 plays a significant role in the development and progression of fibrosis and tumor.

Key Points: 
  • As an important inflammation factor, IL-11 plays a significant role in the development and progression of fibrosis and tumor.
  • Studies have shown that high expression of IL-11 is associated with the prognosis of various tumors such as lung cancer, hepatic cancer, and colorectal cancer.
  • IL-11 not only promotes the growth of tumor cells through the STAT3 pathway but also has a significant impact on immune cells in the tumor microenvironment.
  • 9MW3811 effectively blocks the formation of the IL-11/IL-11Ra/gp130 ternary complex by binding to IL-11, thereby inhibiting the activation of downstream signaling pathways.

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, March 12, 2024
Primary sclerosing cholangitis, Patient, PSC, Integrin, IPF, Idiopathic pulmonary fibrosis, European, Therapy, Drug development, Clutch (eggs), Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis (IPF). The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial. Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).

Key Points: 
  • The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial.
  • Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).
  • “The implementation of BEACON-IPF as an accelerated pivotal, adaptive Phase 2b/3 trial design is another example of our efficient approach to drug development,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics.
  • This facility, along with the Company’s December 31, 2023 cash and cash equivalents of $495.7 million are expected to fund Pliant through 2026.

Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

Retrieved on: 
Friday, March 15, 2024
Diagnosis, Uncertainty, Histology, Growth, Infertility, Cyst, Disease, University, Pelvis, Endometrioma, Patient, Rectum, Abdomen, Laparoscopy, Endometriosis, Society, Integrin, Woman, SRI, Pain, University of Oxford, FDA, Medical imaging

The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.

Key Points: 
  • The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.
  • Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford added: "Endometriosis is a common disease affecting many millions of women worldwide with pain and infertility.
  • Therefore, a novel imaging tool to assist healthcare professionals in identifying or ruling out the disease is urgently needed."
  • At the Endometriosis CaRe Centre at the University of Oxford our studies focus on identifying novel genetic, diagnostic and therapeutic targets for endometriosis.

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Therapy, IPF, SAN, Week, Research, Integrin, PSC, Investment, DMD, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, Duchenne muscular dystrophy, ELF, Cirrhosis, Tumor microenvironment, Patient, Novartis, TGF, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.
  • Positive safety and efficacy data from 320 mg dose cohort of INTEGRIS-PSC Phase 2a trial in patients with primary sclerosing cholangitis (PSC).
  • At a once-daily dose of 320 mg, bexotegrast was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events.
  • The increase was due to higher operating expenses coupled with a decrease in collaboration revenues under the Novartis collaboration during the quarter.

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Retrieved on: 
Tuesday, December 19, 2023
Janus, Disease, Tyrosine kinase inhibitor, Dicarboxylic acid, Antibody, Inflammatory bowel disease, B cell, Gastrointestinal disease, Patent, Integrin, Gastrointestinal tract, SAN, Therapy, JAK, GI, IP, Device, Janus kinase, Peptide, United States patent law, Chemokine, Ulcerative colitis, Pharmaceutical industry

SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under development.
  • 17/313,339, entitled “Treatment of a Disease of the Gastrointestinal Tract with a JAK Inhibitor and Devices,” will issue as US Patent No.
  • The patent covers many JAK inhibitors, including those that are approved or in development for a range of indications.

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

Retrieved on: 
Monday, November 13, 2023
Primary biliary cholangitis, Hepatology, SAN, Myofibroblast, Therapy, PSC, Primary sclerosing cholangitis, PBC, Cirrhosis, AASLD, Toronto Centre, ALK5, Patient, Wound healing, Liver disease, Gene expression, TGF, Liver, Non-alcoholic fatty liver disease, Fibrosis, Trial of the century, ELF, Integrin, Safety, Pharmaceutical industry

These posters were presented at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • These posters were presented at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD).
  • “Our presentations at the Liver Meeting feature preclinical and clinical work supportive of bexotegrast’s antifibrotic mechanism of action in liver fibrosis,” said Éric Lefebvre, M.D., Chief Medical Officer of Pliant.
  • An αVβ1-selective integrin inhibitor was evaluated on fibrotic and non-fibrotic human liver tissue to assess the effects on cell populations present in fibrotic human liver tissue.
  • The effects of bexotegrast (PLN-74809), a dual inhibitor of integrins αVβ6 and αVβ1, were assessed on human liver tissue to characterize the response of unique cell populations in fibrotic primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
ALP, Safety, SAN, Therapy, PSC, Primary sclerosing cholangitis, Data monitoring committee, AASLD, Investment, Biotechnology, Serum, Patient, DSMB, Idiopathic pulmonary fibrosis, Tumor microenvironment, Research, Enrollment, Week, IPF, Pharmacokinetics, Liver, TGF, Alkaline phosphatase, Novartis, Duchenne muscular dystrophy, Biomarker, Cirrhosis, Integrin, ELF, DMD, Fibrosis, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2023 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2023 financial results.
  • “The third quarter was highlighted by positive interim data from the INTEGRIS-PSC trial of bexotegrast demonstrating a favorable safety profile and encouraging antifibrotic activity in PSC.
  • Positive safety and efficacy data from INTEGRIS-PSC Phase 2a trial in patients with primary sclerosing cholangitis (PSC).
  • These data were selected for an oral late-breaker presentation at next week’s American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023.

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Retrieved on: 
Thursday, November 9, 2023
Survival, PNAS, IND, Stanford University, Patent, SOD1, KTTA, Clinical professor, Behavior, National academy, CNS, Natalizumab, Research, HIV disease progression rates, FN, Oregon Health & Science University, Disease, ALS, Multiple sclerosis, Integrin, Patient, Mayo Clinic, MS, SAN, Central nervous system, Pharmaceutical industry, Pasithea (Charites), Nature

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody (mAb) that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Scientists at Pasithea have performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS.
  • This work included further validation of α5β1 integrin as a target in both familial (SOD1) and sporadic (TDP-43) ALS mouse models with reproducible improvements on behavior and survival.
  • Extensive mechanism of action studies link disease model efficacy to effects on the migration and adhesion of immune cells.
  • Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea commented, “We have chosen the most optimal anti-α5β1 humanized mAb for the treatment of both sporadic and familial ALS.

Morphic Corporation: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Monday, November 6, 2023
Integrin, Autoimmunity, Fibrosis, Ulcerative colitis, Pharmaceutical industry

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Morphic Holding, Inc. (NASDAQ: MORF) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors. Morphic investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Morphic Holding, Inc. (NASDAQ: MORF) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors.
  • Morphic investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

Retrieved on: 
Monday, November 6, 2023
Patient, Fibroblast, Therapy, Pembrolizumab, LAP, TGF, Assay, HIV disease progression rates, Pharmacokinetics, PDA, SITC, Tissue, Immunotherapy, Integrin, Safety, Society, Combination therapy, Gene expression, Prognosis, CAF, SAN, Pharmaceutical industry, Cancer

These posters were presented as part of the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held November 1 - 5, 2023.

Key Points: 
  • These posters were presented as part of the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held November 1 - 5, 2023.
  • Expression of αvβ1 protein was evaluated across a diverse set of human tumor tissues and cancer-associated fibroblasts (CAF) to investigate its functional role in cancer biology.
  • PLN-101095, a selective small molecule inhibitor of αvβ8 and αvβ1 integrins, was evaluated in combination with anti-mPD-1 on fibrotic markers in the EMT6 tumor model.
  • PLN-101095, a selective small molecule inhibitor of αvβ8 and αvβ1 integrins, was assessed in preclinical models of pancreatic ductal adenocarcinoma (PDA).